FDA approves Dupixent for allergic fungal rhinosinusitis
by Lori Solomon edited by Stephanie Baum, reviewed by Robert Egan Editors’ notes The GIST Add as preferred source The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery. Dupixent received priority review […]
FDA approves Dupixent for allergic fungal rhinosinusitis Read More »
